My Favorite Way to Play the Pharmaceuticals

Before you go, we thought you'd like these...
Before you go close icon

In the following video, Fool contributor Matt Thalman discusses how he plays the pharmaceutical industry. While the likes of Pfizer and Merck may be the first names that come to mind, Matt doesn't think they're the best investing choices, as he thinks the major drug companies don't offer the correct amount of reward to compensate for their risk.

That's why Matt prefers generic pharmaceutical companies. Mylan Pharmaceuticals and Teva Pharmaceutical Industries are two of the big names in this market, and Matt says investors might consider looking here for a combination of less long-term risk but a strong potential for good returns.

More Foolish insight on pharmaceuticals
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab a copy of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

The article My Favorite Way to Play the Pharmaceuticals originally appeared on

Fool contributor Matt Thalman owns shares of VIVUS and Mylan. Follow Matt on Twitter: @mthalman5513. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading